Vigil Neuroscience, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022
Assets
Current assets:
Cash and cash equivalents
Marketable securities
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Financing lease right-of-use assets
Restricted cash
Other assets
Total assets
Liabilities, Convertible Preferred Stock and Stockholders' Equity
Current liabilities:
Accounts payable
Contract liability
Accrued expenses and other current liabilities
Operating lease liabilities
Financing lease liabilities
Total current liabilities
Operating lease liabilities, net of current portion
Finance lease liabilities, net of current portion
Total liabilities
Stockholders' equity:
Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2025 and December 31, 2024; 47,730,884 shares issued as of June 30, 2025 and 40,931,085 shares issued as of December 31, 2024; and 47,686,561 shares outstanding as of June 30, 2025 and 40,886,762 shares outstanding as of December 31, 2024
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity

Comments